The Effect and the Pharmacogenomics Study of Liraglutide in Obese Patients

NCT04839237 · Withdrawn

Last updated 2026-05-28

This clinical trial is testing the effects of the medication liraglutide on weight change in adults who are obese over a period of 3 months.

Status Withdrawn Stopped before any participant enrolled.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) treatment study

Who can join Ages 18–65 · all sexes

Timeline Started 2017-12 · est. completion 2021-12

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT04839237 ↗

Description as written by the study sponsor.

This studay evaluates the effect of liraglutide in the treatment of obese patients ande the influence of genetic factors on the curative effect.Half of participants will receive Liraglutide alone,while the other half who can not achieving adequate glycaemic control will receive Liraglutide and metformin in combination.

Treatments tested

Liraglutide also known as Victoza Drug

The treatment of Liraglutide lasted three months,During the first week: 0.6mg per day, subcutaneous injection;During the second week: 1.2mg per day, subcutaneous injection; From third week onwards,1.8mg per day, subcutaneous injection.
Liraglutide;metformin also known as Victoza;Glucophage Drug

The treatment of Liraglutide combined with metformin lasted three months.For Liraglutide,during the first week: 0.6mg per day, subcutaneous injection;during the second week: 1.2mg per day, subcutaneous injection; from third week onwards,1.8mg per day, subcutaneous injection.For metformin,during three months:0.5g each time, 3 times per day,oral.

Main thing measured	Weight Change at 3 months
Sponsor	Xiangya Hospital of Central South University
Conditions studied	Obesity
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04839237 ↗